A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
A Phase IIa Multicenter, Randomized, Double-blind, Double-dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater
-
-
California
-
Beverly Hills, California, Forenede Stater
-
Glendale, California, Forenede Stater
-
San Diego, California, Forenede Stater
-
-
Florida
-
Bradenton, Florida, Forenede Stater
-
Maitland, Florida, Forenede Stater
-
Orlando, Florida, Forenede Stater
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater
-
-
Idaho
-
Eagle, Idaho, Forenede Stater
-
-
Illinois
-
Chicago, Illinois, Forenede Stater
-
-
Kansas
-
Prairie Village, Kansas, Forenede Stater
-
Topeka, Kansas, Forenede Stater
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater
-
Shreveport, Louisiana, Forenede Stater
-
-
New Jersey
-
Nutley, New Jersey, Forenede Stater
-
-
New York
-
Brooklyn, New York, Forenede Stater
-
Cedarhurst, New York, Forenede Stater
-
Fresh Meadows, New York, Forenede Stater
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater
-
-
Oregon
-
Portland, Oregon, Forenede Stater
-
-
Pennsylvania
-
Norristown, Pennsylvania, Forenede Stater
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater
-
-
Texas
-
Austin, Texas, Forenede Stater
-
Irving, Texas, Forenede Stater
-
-
Virginia
-
Richmond, Virginia, Forenede Stater
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosed with moderate to severe major depressive disorder
- Willing to use acceptable methods of birth control throughout the study and for 3 months after
- In good general health
Exclusion Criteria:
- No history or current diagnosis of other psychiatric conditions such as bipolar disorder, psychotic disorder, general anxiety disorder, anorexia, obsessive compulsive disorder, post traumatic stress disorder, antisocial personality disorder, mental retardation, pervasive developmental disorder, or cognitive disorder
- No history or presence of drug abuse
- No use of prescription medications or herbal medications other than hormone replacement therapies
- No prior history of heart disease or current significant blood, lung, kidney, liver, heart, breathing, neurologic or thyroid disorders
- No patients who are either pregnant or nursing
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Form= capsule, route= oral use.
Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
|
|
Aktiv komparator: Escitalopram
|
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
|
|
Eksperimentel: JNJ-18038683
|
Form= capsule, route= oral use.
Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Explore the effectiveness of JNJ-18038683 in patients with moderate to severe depression as determined by accepted clinical assessments done throughout the study.
Tidsramme: Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.
|
Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Explore the safety and tolerability of JNJ-18038683 in patients with moderate to severe depression by assessing adverse events, vital signs, laboratory test results, ECGs and physical exams.
Tidsramme: Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.
|
Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Adfærdsmæssige symptomer
- Psykiske lidelser
- Stemningsforstyrrelser
- Depression
- Depressiv lidelse
- Depressiv lidelse, major
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Psykotropiske stoffer
- Serotoninoptagelseshæmmere
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Serotoninmidler
- Antidepressive midler
- Antidepressive midler, anden generation
- Citalopram
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CR014617
- C-2007-007 (Anden identifikator: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .